Gene expression changes induced by the BET inhibitor GSK525762 and/or the MEK inhibitor trametinib in cancer cell lines.. Gene expression changes induced by the BET inhibitor GSK525762 and/or the MEK inhibitor trametinib in cancer cell lines.

Transcriptional changes were analyzed in two colorectal cancer, two pancreatic cancer, and one small cell lung cancer cell line following treatment with the BET inhibitor GSK525762 and/or the MEK inhibitor trametinib using Affymetrix Human Genome U133 Plus 2.0 Arrays. Overall design: The RKO colon cancer cell line was treated with DMSO (control), 500nM GSK525762, 30nM trametinib, or a combination of two agents for 24 or 96 hours. The colon cancer cell line COLO 201 and the pancreatic cancer cell lines HPAF-II and BxPC-3 were treated with DMSO, 500nM GSK525762, trametinib (3nM for COLO 201; 10 nM for HPAF-II and BxPC-3), or a combination of two agents for 96 hours. The small cell lung cancer cell line NCI-H510 was treated with 1000nM GSK525762 for 24 or 96 hours. Two biological replicates are included for each treatment group.